Life After Transient Ischemic Attack (LATIA)

Life After Transient Ischemic Attack: A 12-months Prospective Cohort Study: The LATIA Cohort

Background: Transient ischemic attack (TIA) is defined as acute neurological symptoms of vascular origin, which resolves completely within 24 hours. However, emerging evidence indicates that up to 1/3 of patients is experiencing (non-focal) lasting symptoms, such as fatigue, depression, and anxiety.

Aim: The aim of this study is to investigate self-reported lasting symptoms after TIA, timing of these symptoms as well as their potential resolution and characterize patients who have high risk for developing these symptoms.

Method: This is a prospective cohort study which will include 350-400 patients with TIA from a single comprehensive stroke care center which serves the population in North Denmark Region, one of five administrative regions in Denmark (Stroke Unit, Aalborg University Hospital). Outcome measures include patient-reported outcomes collected at discharge, 3, 6 and 12 months and semi-structured interviews with a selected sample of patients.

Perspective: This study will provide much needed insights into the development of lasting symptoms in patients with TIA in a cohort with presumed high external validity. Based on these results, a person-centered intervention will be designed to support the return to everyday life for patients with TIA.

Study Overview

• Status: Active, not recruiting
• Conditions: Quality of Life; Transient Ischemic Attack

Detailed Description

Background:

In Denmark approximately 4.000 patients every year are diagnosed with Transient Ischemic Attack (TIA). In Denmark the time-based definition of TIA is used and based on a clinical assessment with acute, often focal neurological symptoms of vascular origin resolving completely within 24 hours. Emerging evidence suggests however, that 1/3 of patients experience lasting symptoms as cognitive impairments, depression, anxiety and/or fatigue, which may impact their ability to return to their normal everyday life. Patients' own perception of a complex and life-altering experience has been identified in the qualitative literature. Some patients experiencing lasting symptoms and alterations in multiple life domains like a feeling of uncertainty, vulnerability, instability and change. According to this review, some patients reported that physical and psychosocial symptoms were not recognized, nor acknowledged by their healthcare professionals. Education for clinicians was recommend to enable them to understand these difficulties, improve interaction and meet the patients' needs.

It is unknown which patients are at increased risk of experiencing the described lasting symptoms when these symptoms arise and how it affects quality of life and return to everyday life. Answers to these questions will allow the design and test of an evidence-based and patient-centered intervention. The ultimate goal will be the creation of an evidence-based guide on how to follow-up and intervene in patients with TIA to ensure the return to their everyday life.

Aim:

The aim of this study is to investigate self-reported lasting symptoms after TIA, timing of these symptoms as well as their potential resolution and characterize patients who have high risk for developing these symptoms.

Furthermore, the socio-economic consequences of TIA will be investigated.

Methods:

The study is designed as a prospective cohort study using mixed methods. As used in the clinical settings in Denmark the time-based definition of TIA will be applied in this study. The diagnosis is defined by acute focal neurological symptoms of vascular origin resolving completely within 24 hours, thereby allowing acute ischemia on imaging.

Recruitment:

All patients diagnosed with TIA from the Stroke Unit, Aalborg University Hospital will be screened for eligibility. Inclusion will follow a twostep approach; 1) using clinical and demographic information from medical records, 2) receiving questionnaires at baseline, 3, 6 and 12 months follow-up.

Baseline characteristics and potential prognostic factors:

A pre-TIA modified Rankin Score (mRS) will be collected to describe the pre-TIA level of function for the included patients.

To investigate which patients are at increased risk of experiencing the lasting symptoms multiple potential prognostic factors will be registered at inclusion. In addition to age and gender these include the following

• Alcohol consumption (<7, 7-14 or >14 units/week) and/or use of narcotics on a weekly basis
• Smoking
• Housing (living in own home, nursing home or other)
• Civil status (living alone, cohabitant (with partner, children, other))
• Cardiovascular risk factors as registered in the Danish Stroke Registry
• Comorbidities in form of other chronic diseases (these will be categorized in neurodegenerative, psychiatric, other)
• Previous stroke
• Previous TIA
• Previous diagnosis or use of medication for depression and/or anxiety
• Previous use of antihypertensive, antiplatelet, oral anticoagulation, statins, antidiabetics
• Acute infarction on imaging
• Highest finished education and corresponding ISCED level.
• Employment status (employed >30 hours/week, employed <30 hours/week, unemployed, retired, other)
• ABCD2 stroke risk stratification.

All interventions initiated after discharge based on the TIA will also be registered.

The diagnosis of TIA in clinical settings is challenging. Therefore, after inclusion of patients the diagnosis of TIA will be verified independently by two stroke neurologists. Disagreement will be resolved by a third senior stroke neurologist. This verification will categorize patients in per protocol confirmed TIA versus non-confirmed TIA allowing for a subgroup analysis of outcome according to this categorization. The verification will be guided by the calculation of The Recognition of Stroke in the Emergency Room (ROSIER) score.

Considerations on sample size:

In the last 5 years, the incidence of TIA registered at the Stroke Unit, Aalborg University Hospital ranged from 369 to 463 patients per year. The content of the project is both to explore non-focal lasting symptoms in patients with TIA as well as prognostic factors, which has not been done previously to this extend. Thus, a specific sample size calculation is therefore not feasible as to many factors are unclear. Based on the average annual admission rate the goal is to include 350-400 patients. There is a time constraint of inclusion for a total of 12 months. This sample-size is deemed sufficient to be able to describe the self-report outcomes across 12 months and provide preliminary data on the proportion of patients in high risk of a poor prognosis.

Data management and statistical analysis:

Data will be handled in REDCap and analyzed in STATA. Baseline descriptive data will be presented as medians and interquartile ranges or frequencies and percentages where appropriate. Missing data will be handled with multiple imputation with chained equations to impute the missing data.

To investigate the development of the included outcomes over time (baseline, 3 months, 6 months and 12 months) a longitudinal regression model will be used. For the primary effect measure, we will implement linear regression, while for supplementary effect measures we will use ordered logistic regression. Because of the repeated measures design the model will be a mixed effects model with a random intercept and fixed treatment variables. After discharge each patient can receive different follow-up and treatment interventions and the implementation of these varies over time. For the primary analysis patients will be assigned to each of the two main treatment tracks at baseline. An additional time-varying variable which indicates the progress of the two treatment tracks categorized as "no further treatment" or "further treatment" will be included in the model. For the subsequent treatment categories, we will conduct similar secondary analyses, but stratified by main treatment arm. For all analyses, the model will include time dependent covariates, thus, potential prognostic factor and baseline characteristic adjustment will be conducted using Marginal Structure models. Study results will be presented with 95% confidence intervals (CI).

To compare results with the existing literature, we will estimate mean and median outcomes with 95% CI for each of the follow-up timepoints

The qualitative semi-structured interviews will be handled in NVivo. An explorative and inductive thematic analysis will be performed by two researchers.

• Study Type: Observational
• Enrollment (Actual): 355

Contacts and Locations

• Study Contact: Name: Birgitte H Ebbesen, PT, MSc; Phone Number: +4551906825; Email: bihc@rn.dk

Study Locations

• Denmark
  • Aalborg, Denmark, 9000
    • Aalborg University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

All patients discharged with TIA during the study inclusion period (February 2022 to February 2023) will be registered in a screening log. Inclusion will use a twostep approach:

1. Patients are asked if clinical and demographic characteristics from their admission to the Stroke Unit can be included in the project
2. Patients are asked if they would like to participate in the 3-, 6-, and 12-months follow-up receiving questionnaires.

Description

Inclusion Criteria:

• Diagnosis of TIA (ICD-10 code DG45, except DG45.3 Amaurosis fugax and DG45.4 Global Transient Amnesia) and for a) accumulated TIA (>1 event within the last 30 days): contact to the healthcare system within 30 days from symptom onset, b) not-accumulated TIA: contact to the healthcare system within 7 days from symptom onset. (as defined in the Danish Stroke Registry)
• Minimum 18 years of age
• Availability for follow-up during the study period
• Able to read and understand Danish
• Able to fill out questionnaires (assessed by the associated healthcare professional)
• Not included in any other research projects

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Presence of fatigue at 3 months	Fatigue using the Fatigue Severity Scale	3 months after event

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Presence of fatigue immediately and 3-, 6- and 12-months after discharge	Fatigue Severity Scale	1-2 weeks, 6- and 12-months after discharge
Presence of fatigue immediately and 3-, 6- and 12-months after discharge	Multidimensional Fatigue Inventory	1-2 weeks, 3-, 6- and 12-months after discharge
Presence of depression and anxiety immediately and 3-, 6- and 12-months after discharge	Hospital Anxiety and Depression Scale	1-2 weeks, 3-, 6- and 12-months after discharge
Patients experience of their quality of life immediately and 3-, 6- and 12-months after discharge	EQ-5D-5L	1-2 weeks, 3-, 6- and 12-months after discharge
Patients experience of well-being immediately and 3-, 6- and 12-months after discharge	WHO-5	1-2 weeks, 3-, 6- and 12-months after discharge
Patients ability to manage everyday life and differences in pre- and post-TIA status immediately and 3-, 6- and 12-months after discharge	The Stroke Specific Quality of Life (third section)	1-2 weeks, 3-, 6- and 12-months after discharge
Level of function immediately and 3-, 6- and 12-months after discharge	Modified Rankin Scale	1-2 weeks, 3-, 6- and 12-months after discharge
The patients ability to obtain information and knowledge to maintain and improve health using questions on health literacy	The European Health Literacy Survey Questionnaire, 12 items	1-2 weeks, 3-, 6- and 12-months after discharge
Patient experienced outcomes of lasting symptoms (if any) and how these affect everyday life	Open question on patients own experience of lasting symptoms affecting everyday life	1-2 weeks, 3-, 6- and 12-months after discharge
Qualitative interviews To provide a deeper understanding of the experiences with and impact of TIA on everyday life	Qualitative interviews will be performed with a sample of 15-20 patients. A purposeful sampling strategy will be used to include patients with different demographics and outcomes, to ensure rich and varied data.	4 months after discharge

Collaborators and Investigators

• Sponsor: Aalborg University Hospital
• Collaborators: Aalborg University
• Investigators: Principal Investigator: Birgitte H Ebbesen, PT, MSc, Aalborg University Hospital

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2022
• Primary Completion (Estimated): March 1, 2024
• Study Completion (Estimated): March 1, 2024

Study Registration Dates

• First Submitted: February 1, 2022
• First Submitted That Met QC Criteria: February 1, 2022
• First Posted (Actual): February 10, 2022

Study Record Updates

• Last Update Posted (Actual): January 30, 2024
• Last Update Submitted That Met QC Criteria: January 29, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: Quality of life; TIA; Transient Ischemic Attack
• Additional Relevant MeSH Terms: Pathologic Processes; Cardiovascular Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Brain Ischemia; Ischemia; Ischemic Attack, Transient
• Other Study ID Numbers: F2022-019

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No